Media coverage about Strongbridge Biopharma PLC (NASDAQ:SBBP) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Strongbridge Biopharma PLC earned a news impact score of 0.08 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.1419800620075 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s analysis:
- Strongbridge Biopharma PLC (SBBP) Expected to Post Earnings of -$0.42 Per Share (americanbankingnews.com)
- Strongbridge Biopharma PLC (SBBP) Set to Announce Earnings on Tuesday (americanbankingnews.com)
- Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November (nasdaq.com)
- Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November 14, 2017 (finance.yahoo.com)
- Strongbridge Biopharma plc to Present at the Stifel 2017 Healthcare Conference (finance.yahoo.com)
Shares of Strongbridge Biopharma PLC (NASDAQ SBBP) traded up $0.10 during trading on Monday, hitting $6.00. The company had a trading volume of 72,500 shares, compared to its average volume of 135,244. The company has a quick ratio of 4.46, a current ratio of 4.63 and a debt-to-equity ratio of 1.89. Strongbridge Biopharma PLC has a one year low of $2.00 and a one year high of $8.85.
A number of brokerages recently commented on SBBP. Zacks Investment Research downgraded Strongbridge Biopharma PLC from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a report on Thursday, August 10th. They set an “outperform” rating and a $12.00 target price for the company. Finally, ValuEngine downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Strongbridge Biopharma PLC has a consensus rating of “Hold” and a consensus target price of $11.81.
TRADEMARK VIOLATION NOTICE: “Strongbridge Biopharma PLC (SBBP) Earns Media Impact Rating of 0.08” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/11/13/strongbridge-biopharma-plc-sbbp-earns-media-impact-rating-of-0-08.html.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.